Soho Flordis International

FBCx® (Alpha-Cyclodextrin)

A dietary fibre to help maintain healthy cholesterol and triglycerides*

Alpha-cyclodextrin (alfadex) is a naturally sourced dietary fibre used in Nuvexa that can help maintain healthy cholesterol and triglyceride levels.*

Alpha-cyclodextrin, also known as alfadex, is a dietary fibre derived from corn, that can help maintain healthy cholesterol and triglyceride levels*.1-3

 

Alpha-cyclodextrin is known, and branded, as patented FBCx (Fat Binding Complexer) – and is used in Nuvexa®.

 

Discover more about FBCx used by Flordis and the key studies that support its benefits when used in Nuvexa.

 

*In healthy individuals.

Alpha-cyclodextrin in history

Alpha-cyclodextrin’s fat binding effect was discovered over a decade ago by researchers at Wayne State University in America. Initial pre-clinical studies5,6 identified that 1 gram of alpha-cyclodextrin may be able to bind up to 9 grams of dietary fat that can then be passed naturally from the body.

These early studies paved the way for further research, including another preclinical study7 suggesting that alpha-cyclodextrin may have a greater binding affinity for the ‘bad’ fats (saturated fats and trans-fats) in the diet.

Alpha-cyclodextrin in history

The specific dietary fibre used by Flordis: FBCx

Alpha-cyclodextrin is a water-soluble dietary fibre derived from corn starch. Cyclodextrins belong to a class of molecules called ‘cage molecules’ – meaning that the core of their structure contains a cavity that can trap other molecules such as fat.

The particular structure of the alpha-cyclodextrin in Nuvexa (FBCx) means that it is able to bind fats in the diet quite well – and is able to trap a higher ratio of fat than most other fibres.

 

Pre-clinical research suggests that the FBCx molecule can bind up to 9 times its own weight in dietary fat.4

The specific dietary fibre used by Flordis: FBCx

Research on how FBCx works

The term ‘fibre’ comprises lots of different substances, however a characteristic of all dietary fibres is that they are resistant to enzymatic digestion and therefore are not usually able to be absorbed into the body.

Dietary fibre can prevent the absorption of certain macronutrients (lipids and carbohydrates), so it can reduce their levels in the blood and provide some other subsequent physiological benefits (i.e. support heart health).

 

FBCx makes use of this characteristic, binding fat from the diet and helping to prevent the body from digesting and absorbing it.

Pre-clinical research suggests FBCx can work by binding to fat to prevent absorption:

 

Dietary fat enters the body.

 

FBCx can bind to the fat and form a complex (Each Nuvexa tablet can bind up to 9g of dietary fat).

 

It is suggested that FBCx shields the fat molecules from the enzymes that usually break it down in the intestines, helping to prevent digestion.

 

The FBCx complex cannot be absorbed by the body and instead passes naturally out of the body.

 

FBCx can help to reduce up to 54 g of dietary fat intake per day – that’s almost 500 calories a day.4

FBCx Molecule

FBCx in clinical trials

Multiple randomised controlled trials of FBCx have demonstrated that it can help maintain healthy levels of cholesterol and triglycerides.* FBCx was also shown to be well tolerated in these clinical trials.

Grunberger 2007 1

47 patients
studied over 3 months

Significant improvement

vs. placebo for:

  • Blood lipid profile Additionally: Positive trend in total cholesterol levels
Comerford 2011 2

28 patients
studied over 2 months

Significant improvement

vs. placebo for:

  • Total cholesterol 'Bad' LDL (low-density lipoprotein) cholesterol levels
Jen 2013* 4

47 patients
studied over 3 months

Positive Dietary Analysis

Supporting earlier pre-clinical studies suggesting that FBCx may help:

  • Bind up to 9:1 ratio of fat to FBCx (1 tablet can bind up to 9g of dietary fat) Reduce dietary fat absorption by up to 54 grams Reduces calorie intake by up to 486 calories

*Recall of data from Grunberger 2007 analysed

Jarosz 2013 3

34 patients
studied over 3 days*

Significant improvement

vs. placebo for:

  • Triglyceride levels (1, 2 and 3 hours after eating)

*Trial analysed the short-term effects of FBCx after 2 meals

Always read the label. Follow the directions for use. If symptoms persist, talk to your health professional.

*FBCx should be used in conjunction with a healthy diet and lifestyle. 

Source to patient

Natural healthcare products can vary considerably depending on how they are produced. Nuvexa is produced according to our 'Source to Patient' philosophy which aims to deliver a high quality and consistent extract, from batch to batch so that you can be confident that it can deliver the health benefits demonstrated in the clinical research.

This helps ensure that the natural medicine you are getting contains the exact ingredient, in the exact same amounts demonstrated in the clinical research. That's the Flordis difference.

FBCx & Nuvexa: A Summary

Consistent quality

Through our rigorous processes, quality controls and extensive testing we help ensure that Nuvexa can provide the health outcomes demonstrated by clinical trials.

10 years of research

Pre-clinical and clinical studies investigating the beneficial effect of alpha-cyclodextrin in binding fats.1-9,11

3 Clinical trials

 Nuvexa clinical studies support its role in maintaining healthy cholesterol and triglyceride levels.1-3

Recommended worldwide

to support healthy cholesterol and triglyceride levels, alongside lifestyle changes.

You might like ...

Cholesterol

Cholesterol

Lifestyle insight

Types, causes, maintenance, and care
Cholesterol

Our source to patient philosophy

We make sure our natural medicines are consistent.

 

Not only do the clinical studies on our products demonstrate real health outcomes, they demonstrate the results you can expect from the same products you see on shelf. It’s all part of our Source to Patient philosophy.

See the steps taken to make our products
References
  1. Grunberger, et al., Diabetes Metab Res Rev 2007;23:56-62.
  2. Comerford KB, et al., Obesity 2011;19:1200-1204.  The study was partially funded by ArtJen Complexus Holdings Corp.
  3. Jarosz PA, et al., Metab Clin Exp 2013;62(10):1443-1447.
  4. Jen KL, et al., Nutr Diet Suppl 2013;5:1-7.
  5. Wagner EM, et al., Metab Clin Exp 2008;57:1046-1051.
  6. Artiss JD, et al., Metab Clin Exp 2006;55:195-202.
  7. Gallaher DD, et al., FASEB J 2007;21:A730.
  8. Gentilcore D, at al., Br J Nutr 2011;106:583-587.
  9. Buckley JD, et al., Ann Nutr Metab 2006;50:108-114.
  10. Background review for cyclodextrins used as excipients . EMA /CHMP/333892/2013. Committee for Human Medicinal Products (CHMP). 20 November 2014.
  11. McGowan MW, et al., Clin Chem 1983;29(3):538-542.